Teniposide plus cisplatin for newly diagnosed central malignant germ cell tumors
Official title: A Single-center, Single-arm, Open-label Study of the Combination of Teniposide Injection and Cisplatin in the Treatment of Newly Diagnosed Patients With Central Malignant Germ Cell Tumors.
Run by Sun Yat-sen University · NCT07188441 · Data updated 2026-11-12
This trial tests whether giving teniposide together with cisplatin helps people newly diagnosed with central malignant germ cell tumors.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 5 Years and up |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Sun Yat-sen University Academic / other |
| Drugs / interventions | chemotherapy, Radiation |
| Locations | 1 site (Guangzhou, Guangdong) |
| Status | Recruiting |
| Started | August 13, 2024 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | September 23, 2025 |
| Trial ID | NCT07188441 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people with a new diagnosis of central malignant germ cell tumor who have at least one measurable lesion, expected survival ≥6 months, and adequate blood counts, liver and kidney function who can give informed consent.
✕Probably not a fit
Patients with poor organ function, inadequate blood counts, pregnancy, inability to tolerate platinum or teniposide, or who have non-central germ cell tumors or extensive prior therapy are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, single-arm Phase 2 trial planning about 40 participants with newly diagnosed central malignant germ cell tumors. Participants receive teniposide 300 mg/m2 given IV over 3–5 days with 500 mL normal saline plus cisplatin 75 mg/m2 given IV over 3–5 days, repeated every 3 weeks for 4–6 cycles, with radiation therapy per standard practice after chemotherapy. The study monitors safety, anti-tumor activity, overall survival and performs drug monitoring to explore biomarkers that might predict response. Eligible patients must have at least one measurable lesion by RANO and adequate blood, liver and kidney function before enrollment.
Why it matters
Potential benefit: If successful, this regimen could extend overall survival and help identify which patients are most likely to benefit using biological predictive markers.
How similar studies have gone: Platinum-based chemotherapy is an established backbone for germ cell tumors, but the specific combination of teniposide plus cisplatin for central malignant germ cell tumors is less well studied and is relatively novel in this setting.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Must have at least one measurable lesion defined by RANO criteria * The initial diagnosis has been confirmed as central malignant germ cell tumor * Expected survival period ≥ 6 months * Absolute neutrophil ≥1.0×10\^9/L; Platelet ≥100.0×10\^9/L * Aspertate aminotransferase and alanine aminotransferase ≤2.5×Upper limit of normal * total bilirubin ≤1.5×Upper limit of normal * Electronic Case Report of Form≥70mL/min/1.73m\^2 * Estimated glomerular filtration rate ≥ 70 mL/min/1.73 m² or normal serum creatinine (Cr) * Women and men with fertility must agree to use appropriate contraceptive methods (hormones or barrier therapy or abstinence) during the study period and within 3 months after the last dose; The pregnancy test of female subjects of childbearing age within 7 days before administration must be negative * Willing and able to read, understand, and sign written informed consent, parents/guardians of child or adolescent subjects have the ability to understand, agree, and sign research informed consent forms and applicable child consent forms before initiating any protocol related procedures Exclusion Criteria: * Patients undergoing any other anti-cancer experimental treatment * Individuals with a history of severe allergies or allergies to any component of the drugs in the past * Previous or concurrent active cardiovascular diseases with clinical significance, including congenital heart disease or pericardial disease, history of heart failure, myocardial infarction, coronary heart disease, heart valve disease, cardiomyopathy, and arrhythmia * Patients with Magnetic Resonance Imaging contraindications * Those who need to receive live virus vaccine during administration * Serious complications and/or underlying diseases * Individuals with poor control of hypertension (under standardized blood pressure reduction protocols, systolic blood pressure ≥ 160mmHg and/or diastolic blood pressure ≥ 100mmHg) * Uncontrolled systemic bacterial, viral, or fungal infections * Patients infected with Human Immunodeficiency Virus(HIV) or syphilis * Patients who have undergone organ transplantation in the past * Pregnant or lactating women * Researchers believe that there are other factors that are not suitable for participating in the experiment
Where it's running
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China Recruiting
Study contacts
- Study coordinator: chengcheng Guo, Doctor of Medicine
- Email: guochch@sysucc.org.cn
- Phone: 020-87343890
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Methionine-Reduced Diet in Solid Tumors (early-phase)
A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.
-
ZW251 for advanced liver, lung, and germ cell cancers
This will test whether ZW251, an antibody-drug conjugate that targets GPC3, is safe and can shrink tumors in adults with advanced hepatocellular carcinoma, squamous cell non-small cell lung cancer, or germ cell tumors.
-
Maintenance zanzalintinib with oral etoposide after high-dose chemotherapy for germ cell tumor
This treatment tests whether daily zanzalintinib together with cycles of oral etoposide can help people with relapsed or refractory germ cell tumors after high-dose chemotherapy and stem-cell transplant.
-
Low-dose aspirin to prevent venous blood clots during chemotherapy for advanced germ cell (testicular) cancer
This trial will see if taking one daily low-dose aspirin (81 mg) during cisplatin chemotherapy prevents venous blood clots over six months in adults up to age 70 with high-risk advanced germ cell or testicular cancer.
-
Creating a database for mediastinal tumors at Peking Union Medical College Hospital
This study is creating a database to help doctors better understand and treat different types of mediastinal tumors by collecting information on their characteristics and imaging results.
-
High-dose chemotherapy for relapsed germ cell tumors
This study is testing if high-dose chemotherapy can help people with relapsed germ cell tumors who didn't respond to their first treatment feel better and live longer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.